MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Solid Tumor.
After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug
After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.